Through early collaborations DeepMind has seen promising signals from researchers using AlphaFold, including DNDi and the University of Portsmouth's Centre for Enzyme Innovation.

True: as of 22 July 2021, DeepMind publications or partner statements document early collaborations in which external researchers, including DNDi (Drugs for Neglected Diseases initiative) and the University of Portsmouth's Centre for Enzyme Innovation, used AlphaFold and reported useful or promising results. Mostly true: early collaborations with promising results are documented, but one of the two named partners is not clearly documented as such. Mixed: collaborations existed, but there is little evidence of promising results, or neither named partner is confirmed. Mostly false: the only evidence is DeepMind's own general statement, with no documented collaborators or outcomes. False: the evidence shows no such early collaborations, or that the named partners did not use AlphaFold.

Set before the research began.

1. E1 DeepMind and EMBL release the most complete database of predicted 3D structures of human proteins EMBL-EBI · 22 July 2021

   “AlphaFold is already being used by partners such as the Drugs for Neglected Diseases Initiative (DNDi), which has advanced their research into life-saving cures for diseases that disproportionately affect the poorer parts of the world, and the Centre for Enzyme Innovation (CEI) is using AlphaFold to help engineer faster enzymes”

2. E2 Enzyme researchers partner with pioneering AI company DeepMind University of Portsmouth · 22 July 2021

   “Being given access to AlphaFold has transformed our research strategy, and we are excited to be partnering with DeepMind to explore other ways in which AI can accelerate our scientific discoveries”

3. E3 Enzyme researchers partner with pioneering AI company DeepMind University of Portsmouth · 22 July 2021

   “AlphaFold provides us with an exciting new library of templates to engineer faster, more stable and cheaper enzymes for plastic recycling.”

4. E4 Nobel prize for chemistry awarded to Demis Hassabis and John Jumper for AlphaFold, an AI model used by DNDi for neglected diseases Drugs for Neglected Diseases initiative (DNDi) · 10 October 2024

   “As early adopters of AlphaFold, DeepMind’s artificial intelligence (AI) protein structure prediction model developed by Hassabis and Jumper, DNDi teams and partners have used the game-changing technology to find innovative ways to accelerate drug discovery”

EMBL-EBI's announcement of 22 July 2021 (E1) says DNDi was already using AlphaFold to advance its research into cures for neglected diseases, and that the Centre for Enzyme Innovation was using it to help engineer faster enzymes. The University of Portsmouth's own statements on the same date (E2, E3) say that access to AlphaFold had transformed the Centre's research strategy and gave it new templates for engineering better plastic-recycling enzymes. DNDi's 2024 statement (E4) calls DNDi an early adopter of AlphaFold, which confirms the collaboration. Both named partners are therefore documented as of the judging date as early collaborators reporting promising results.